

The Paediatric IBD Porto Group

SPGHAN

11-14 September 2019 | Budapest · Hungary | www.pibdcongress.org

# Abstract Submission Guidelines

Please read this information carefully before proceeding to the online abstract submission. Only abstracts that meet these guidelines can be accepted for the meeting.

## 1. IMPORTANT DATES

- Submission deadline: Monday, 13 May 2019, 23:59 CET  $\geq$ Abstracts received after the deadline will not be accepted!
- Abstracts Review: 20 May 2019 31 May 2019  $\geq$
- Notification of authors: from 13 June 2019  $\triangleright$

## 2. ABSTRACT TOPICS

During the online abstract submission you will have to select one of the following topics:

Etiopathogenesis, basic science and translational medicine

Epidemiology

Diagnosis, differential diagnosis and classification

Clinical presentations and associated manifestations

Treatment

Follow-up and monitoring

Quality of care, transition and Psychosocial aspects

Nurses and dietitians

Case reports

The correct topic must be selected to ensure correct scoring. The content of the abstract must be topic related.



The Paediatric IBD Porto Group

SPGHAN

11-14 September 2019 | Budapest · Hungary | www.pibdcongress.org

## 3. CONTENT AND FORMAT OF YOUR ABSTRACT

- a) The official meeting language will be English. Abstracts must be submitted in English. Please ensure keywords within your abstract title are written in the British-English variation; for example Paediatric, Coeliac (not American-English: Pediatric, Celiac).
- b) An abstract can be submitted to the 5<sup>th</sup> International Symposium on PIBD if it has not been published previously, except national conferences or major ones (ESPGHAN, UEG, ECCO, DDW, EASL, ASLD).
- C) The abstract cannot contain more than 3,350 characters (including blank spaces and punctuation).
- The abstract has to be entered in the online form of the abstract tool with the following structure: d)
  - Objectives and study
  - Methods
  - Results
  - Conclusion

Authors affiliations and abstracts title will not be part of the abstract document (blind review), but have to be indicated in separate fields during the abstract submission (see above).

One table or one figure (jpg or png) can be included. The table has the following restrictions: e) Max. number of columns: 10 Max. number of rows: 10

The table / figure will not reduce the number of available characters.

Conflict of interest disclosure f)

If the research or one of the co-authors has a conflict of interest (paid work, presentation by industry employee, industry sponsored presentation, grants received from industry related to the presentation), this must be clearly stated. Please indicate the disclosure of interest for each co-author of your abstract during the abstract online submission.

- g) Abstracts must contain data and meet international ethical standards.
- h) Abbreviations should be defined.
- Trade names cannot be mentioned in the title. However, trade names in brackets will be accepted in the body i) of the text.
- Please ensure that your abstract does not contain spelling, grammatical or scientific errors. No corrections are i) possible after the submission deadline. The abstract text as well as the abstract title and the list of authors will be reproduced exactly as submitted. No proof reading will be done.



The Paediatric IBD Porto Group

ESPGHAN

11-14 September 2019 | Budapest · Hungary | www.pibdcongress.org

#### 4. ABSTRACT SUBMISSION

- a) Abstracts can only be submitted online via the <u>online abstract submission tool</u>. All further information can be also found in the section "Call for abstracts" on the official <u>PIBD 2019 congress</u> <u>homepage</u>. Abstracts sent by post or email will not be accepted. No exceptions will be made.
- b) Technical Requirements

The abstract submission system is designed to run on a number of internet browsers, but it is recommended to use the latest versions of Google Chrome, Microsoft Internet Explorer, Mozilla Firefox or Apple Safari. JavaScript need to be enabled to maximize user friendliness.

c) You can interrupt your online submission at any time and continue it later – your data will be saved. You can re-edit/modify your abstract after final submission but only until the submission deadline. After the deadline (13 May 2019) no corrections or changes of the abstract title and the co-authors can be made anymore.

#### 5. AFTER YOUR SUBMISSION

- a) After successful submission of your abstract you will receive an automatic confirmation by email.
- b) The reviewers will judge the abstracts according to the relevance to PIBD 2019. They will assess the standard of English, objectivity of statements, description of the work, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall impression.
- c) The submitting author will be notified from 13 June 2019 onwards whether the abstract has been accepted. Notifications will be sent via email to the email address of the abstract submitter provided (corresponding author) during the online submission. It is the authors' responsibility to ensure that emails from PIBD and from the submission tool (abstractserver.com) can reach them. Within the notification authors will be informed of the date, time and form of their presentation.

### 6. PUBLICATION POLICY

All abstracts accepted for presentation (oral or poster) will be published on the <u>congress website</u>. The abstracts for the 5<sup>th</sup> International Symposium on PIBD will also be published in the *Journal of Pediatric Gastroenterology and Nutrition* (*JPGN*). Please note that the abstracts will be published at the beginning of September.

### 7. CONTACT

If you have any questions, please do not hesitate to contact us at pibd@eurokongress.de.

#### General rules on scientific abstract presentations at PIBD meetings

PIBD provides platforms for oral and poster presentations of scientific findings, usually submitted in abstract form, at the international symposium and other meetings. The presentations should focus on the presentation and discussion of scientific data and should not in any way be abused for marketing or advertising purposes. Any financial support by commercial companies and any other ties to commercial companies such as employment and honoraria must be transparently disclosed. The use of brand names of commercial products should be avoided, unless the disclosure of brand names is necessary for the understanding of the abstract or presentation in which case the brand name should not be used more than once. The name of companies linked to the research should be disclosed but <u>no company</u> <u>logos should be used in scientific presentations</u> in order to avoid even the suspicion of undue promotional activities.